Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study

NCT02614196 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

986

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Galcanezumab
DRUG: Placebo

Sponsor

Eli Lilly and Company